There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rigel (NASDAQ: RIGL), ChemoCentryx (NASDAQ: CCXI) and Audentes Therapeutics (NASDAQ: BOLD) with bullish sentiments.
Rigel (NASDAQ: RIGL)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (NASDAQ: RIGL), with a price target of $7.50. The company’s shares closed yesterday at $3.70.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -14.3% and a 32.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Rigel is Strong Buy and the average price target is $8, representing an 116.2% upside.
In a report issued on April 17, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $6 price target.
See today’s analyst top recommended stocks >>
ChemoCentryx (NASDAQ: CCXI)
H.C. Wainwright analyst Edward White initiated coverage with a Buy rating on ChemoCentryx (NASDAQ: CCXI) today and set a price target of $20. The company’s shares closed yesterday at $11.
According to TipRanks.com, White is a 5-star analyst with an average return of 24.5% and a 52.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Mirati Therapeutics.
ChemoCentryx has an analyst consensus of Hold.
Audentes Therapeutics (NASDAQ: BOLD)
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Audentes Therapeutics (NASDAQ: BOLD) today and set a price target of $37. The company’s shares closed yesterday at $36.65.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.7% and a 47.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $31.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
